Pharmaceutical Care for One Child with Kawasaki Disease Suspected of Bacterial Meningitis
- VernacularTitle:1例疑似化脓性脑膜炎川崎病患儿的药学监护
- Author:
Mei ZHANG
;
Wei LEI
;
Dong DONG
;
Zheng YUAN
- Keywords:
Upper respiratory tract infection;
Kawasaki disease;
Cerebrospinal fluid;
Reasonable drug application
- From:
China Pharmacist
2017;20(6):1089-1091
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To discuss the rational drug application of Kawasaki disease in children with upper respiratory tract infection in order to provide reference for the therapy of Kawasaki disease suspected of bacterial meningitis.Methods: The medical record of a 2-year-old boy with Kawasaki disease was retrospectively analyzed, and the anti-infection treatment was analyzed and evaluated.Meanwhile, the mechanism of elevated leukocyte count in cerebrospinal fluid (CSF)of children with incomplete Kawasaki disease was discussed.The pharmaceutical care and treatment results in the diagnosis and treatment process were analyzed as well.Results: The anti-infective therapy in early stage was reasonable as the early symptoms of respiratory tract infection in the child were obvious, however, the choice of aztreonam was defective.On the premise of the clinical diagnosis of Kawasaki disease and excluding bacterial meningitis, the medication was timely adjusted.Finally, the symptoms of the child were improved.Conclusion: The application of anti-infection drugs should be reasonable in clinics, and the abnormality in cerebrospinal fluid should be paid more attention in children with Kawasaki disease.It is necessary to strengthen clinical observation and pharmaceutical care in order to guarantee the safety of medication for patients.
